Narbup 2 & 8 Mg 2 mg & 8 mg Sublingual Tablet
PDF Leaflet Revision Date: 27 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Substitution treatment for opioid drug dependence.
Dosage (summary)
Starting dose: 1-2 tablets of NARBUP 2 mg/0.5 mg; max daily dose: 24 mg.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding should be discontinued.
Key Drug Interactions
- Benzodiazepines
- CNS depressants
- Serotonergic agents
- CYP3A4 inhibitors/inducers
Contraindications
- Hypersensitivity to buprenorphine or naloxone
- Severe respiratory insufficiency
- Severe hepatic insufficiency
- Acute alcoholism
Common side effects
- Withdrawal symptoms
- Constipation
- Nausea
- Dizziness
- Sweating
Counselling Points
- Use only as prescribed.
- Avoid alcohol and CNS depressants.
- Monitor for signs of withdrawal or overdose.
Serious warnings
- Risk of respiratory depression
- Potential for misuse and dependence
- Caution in patients with compromised respiratory function
Important Disclaimer
The Narbup 2 & 8 Mg 2 mg & 8 mg Sublingual Tablet professional information leaflet below is the property of Adcock Ingram Critical Care and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
